Opinion|Videos|March 7, 2025
Optimizing BTK Inhibitor Treatment: Managing Adverse Effects and Adherence
Panelists discuss proactive measures that health care teams can implement to manage adverse events associated with Bruton tyrosine kinase (BTK) inhibitors, such as early monitoring, dose adjustments, and supportive care, while emphasizing the importance of patient education to improve adherence and ensure positive treatment outcomes.
Advertisement
Episodes in this series
- What proactive measures can health care teams implement to manage adverse events associated with BTK inhibitors, ensuring both treatment adherence and patient quality of life?
- How can oncologists better educate patients about BTK inhibitors to improve adherence and support positive treatment outcomes?
Advertisement
Related Content
Advertisement
Advertisement
Advertisement
Trending on AJMC
1
Daraxonrasib Clears FDA as First RAS-Targeted Pancreatic Cancer Drug
2
As GLP-1 Costs Climb, Medicare Part D Plans Face a Reckoning
3
ACO-SWITCH to Evaluate Tafamidis-to-Acoramidis Switch in ATTR-CM
4
Early Secukinumab Sustains Psoriasis Clearance a Year After Stopping
5